FI940867A0 - Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksia - Google Patents
Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksiaInfo
- Publication number
- FI940867A0 FI940867A0 FI940867A FI940867A FI940867A0 FI 940867 A0 FI940867 A0 FI 940867A0 FI 940867 A FI940867 A FI 940867A FI 940867 A FI940867 A FI 940867A FI 940867 A0 FI940867 A0 FI 940867A0
- Authority
- FI
- Finland
- Prior art keywords
- nucleotide sequences
- retroviral vectors
- recombinant retroviruses
- hiv inhibitory
- inhibitory antisense
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2193693A | 1993-02-25 | 1993-02-25 | |
US19035094A | 1994-02-01 | 1994-02-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
FI940867A0 true FI940867A0 (fi) | 1994-02-24 |
FI940867A FI940867A (fi) | 1994-08-26 |
Family
ID=26695271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI940867A FI940867A (fi) | 1993-02-25 | 1994-02-24 | Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksia |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0612844A2 (fi) |
JP (1) | JPH06335392A (fi) |
KR (1) | KR940019314A (fi) |
AU (1) | AU5639494A (fi) |
FI (1) | FI940867A (fi) |
IL (1) | IL108719A0 (fi) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018854A1 (en) * | 1994-01-05 | 1995-07-13 | Gene Shears Pty., Ltd. | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
AU2133695A (en) * | 1994-04-06 | 1995-10-30 | Sadna Joshi-Sukhwal | Inhibition of hiv-1 multiplication in mammalian cells |
US20020058636A1 (en) * | 1994-09-21 | 2002-05-16 | Geoffrey P. Symonds | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
EP1380650B1 (en) * | 1995-11-28 | 2010-01-20 | The Johns Hopkins University School Of Medicine | Conditionally replicating viral vectors and their use |
US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
EP0914423A2 (en) * | 1996-06-06 | 1999-05-12 | Novartis AG | Inhibition of hiv-1 replication by antisense rna expression |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
GB9803351D0 (en) * | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
US7244570B2 (en) | 1998-08-04 | 2007-07-17 | Luminex Molecular Diagnostics, Inc. | Methods and compositions for modulating “marginally indiscriminant” hybridizations |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
CA2352532C (en) | 1998-11-27 | 2014-10-14 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
US6911429B2 (en) | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
EP1179082A2 (en) * | 1999-05-21 | 2002-02-13 | Oxford Biomedica (UK) Limited | Improved retroviral production by inhibition of the enveloppe cell receptor |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
CA2446112C (en) | 2001-05-08 | 2011-04-26 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
US7345025B2 (en) | 2001-07-10 | 2008-03-18 | Johnson & Johnson Research Pty. Limited | Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
US7994144B2 (en) | 2001-07-10 | 2011-08-09 | Johnson & Johnson Research Pty, Limited | Process for the preparation of a composition of genetically modified hematopoietic progenitor cells |
CA2464527A1 (en) | 2001-10-26 | 2003-08-14 | Id Biomedical Corporation Of Washington | Multivalent streptococcal vaccine compositions and methods for use |
WO2021211952A2 (en) * | 2020-04-16 | 2021-10-21 | Massachusetts Institute Of Technology | Compositions and methods for sequestering viruses |
-
1994
- 1994-02-21 IL IL10871994A patent/IL108719A0/xx unknown
- 1994-02-24 AU AU56394/94A patent/AU5639494A/en not_active Abandoned
- 1994-02-24 EP EP94301315A patent/EP0612844A2/en not_active Withdrawn
- 1994-02-24 FI FI940867A patent/FI940867A/fi unknown
- 1994-02-25 KR KR1019940003486A patent/KR940019314A/ko not_active Application Discontinuation
- 1994-02-25 JP JP6051115A patent/JPH06335392A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0612844A2 (en) | 1994-08-31 |
JPH06335392A (ja) | 1994-12-06 |
KR940019314A (ko) | 1994-09-14 |
FI940867A (fi) | 1994-08-26 |
IL108719A0 (en) | 1994-08-26 |
AU5639494A (en) | 1994-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI940867A (fi) | Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksia | |
DK188991D0 (da) | Terapeutisk virksom kort, dobbeltstrenget rna | |
DK0821690T3 (da) | Nukleotidanaloger til behandling af virusinfektioner | |
MA22905A1 (fr) | Nouvelles sequences d'adn . | |
FR2689694B1 (fr) | Laser doublé en fréquence, à fréquence unique. | |
DE3788847T2 (de) | Hybrid-Promotor, expressionskontrollierende DNS-Sequenz und Expressions-Vektor. | |
AU4214289A (en) | Viral nucleotide sequences | |
NO881588D0 (no) | Piezoelektrisk bryter. | |
DK197990A (da) | Oploesningsmiddelmodstandsdygtige, straalingshaerdelige belaegninger | |
DK198387A (da) | 1-hydroxy-2-pyridoner, deres fremstilling og anvendelse samt ved fremgangsmaaden anvendelige mellemprodukter og disses fremstilling | |
HUP0100087A3 (en) | Nucleosides analogues, the use thereof for producing medicaments useful against retroviral infections and hepatitis b virus and the same medicaments | |
ES8800985A1 (es) | Procedimiento de preparar proteinas. | |
DK95188D0 (da) | Dna-segment, som fremkalder hoejfrekvens-transduktion af rekombinant-rna-vektorer | |
IT8667478A1 (it) | Nuove metafenilendiammine nitrate, alogenate in posizione 6, composizioni che le contengono e loro impiego per la tintura di fibre cheratiniche. | |
FR2682967B1 (fr) | Nouveau promoteur de m. paratuberculosis. son utilisation pour le clonage et l'expression de sequences nucleotidiques. | |
DK221789D0 (da) | Prolaegemidler af 2',3'-didehydro-2',3'-dideoxynucleosider | |
FI892233A (fi) | Behandlingsfoerfarande foer keramiska fibrer. | |
ZA941287B (en) | Expression constructs containing HIV inhibitory antisense and other nucleotide sequences, retroviral vectors and recombinant retroviruses containing same. | |
FI892289A (fi) | Substituerade azoltioetrar, deras framstaellning och deras anvaendning som skadedjursbekaempningsmedel. | |
DE69022165D1 (de) | Klonierungs-Plasmid-Vektor, Primer-Vektor davon und Herstellungsverfahren einer cDNA-Bank. | |
FR2692349B1 (fr) | Gyromètre à poutre vibrante, à excitation piézo-électrique. | |
IL99172A0 (en) | Antisense oligonucleotides which are active as antiviral agents | |
NO902926D0 (no) | Peptid tilsvarende hiv-env 583-599, og analoger derav, samt anvendelser av peptidene. | |
IT1227876B (it) | Peptidi ad attivita' anti hiv. | |
SE9603702D0 (sv) | Alfavirus-retrovirus vektorer |